Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to expand seasonal vaccine franchise from three to up to six approved products by 2028 Targets readouts from nine ongoing Phase 2 and Phase 3 clinical studies in its oncology pipeline, including three Phase 3 programs for intismeran autogene Further improves 2026 and 2027 expected GAAP operating expenses by approximately $0.5 billion each year on path to targeted cash breakeven in 2028 CA ...